Derivative exercise or conversion — not an open-market buy.
Traded Aug 19, 2026 · Filed Aug 20, 2026
Incyte's President, Global Head of R&D sold $1.36M of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,356,174
Shares × reported transaction price
22 days after results of Jul 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $128.47 on Aug 19, 2026, within 2% of its 52-week high, after a 10% rise over the previous 30 trading days
52-week range $81.66 (Sep 25, 2025) to $129.93 (Jul 28, 2026), 97% of the way up, from 251 adjusted closes. 30 trading days earlier: $117.26 on Jul 8, 2026. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.7% | +0.5% | -3.2% |
| 30 days | -2.5% | +1.0% | -3.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.